TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02184156
Drug: 4 mL injection of Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02762617
Drug: Placebo intravaginal ring (IVR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
Study: NCT02581072
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically once
Study: NCT01938235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus and 24-hour infusion of placebo
Study: NCT00642421
Drug: C2L-OCT-01 PR, 10 or 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
Study: NCT00642421
Drug: C2L-OCT-01 PR, 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
Study: NCT00561171
Drug: SPP635
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral once daily
Study: NCT03782480
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravaginal inserts
Study: NCT03462836
Drug: IV PCA only apply
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.
Study: NCT01647711
Drug: Dose escalation followed by treatment with MTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed 3+3 dose escalation; expansion of MTD cohort
Study: NCT01052324
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After topical airway anesthesia with 10 % lidocaine in nostril and oropharyx, 1.5\~2.0 mg of IV midazolam is injected. Awake nasotracheal fiberoptic intubation is performed with target-controlled infusion of remifentanil. Initial effect site concentration is 3.0 ng/ml. Smooth intubation is defined as absence of persistent cough with head elevation and defensive movement of extremities. In case of smooth intubation, effect site concentration is decreased by 0.5 ng/ml for the subsequent case. If intubation is not smooth, effect site concentration is increased by 0.5 ng/ml for the subsequent case. EC50 of remifentanil is determined using Dixon's up-and-down method.
Study: NCT02999984
Drug: PEG-ADA ERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
Study: NCT02524184
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an identical placebo per day for 7 days
Study: NCT03235609
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl used with propofol for sedation
Study: NCT00455962
Drug: Estradiol steroid infusion
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
Study: NCT01337765
Drug: BEZ235 + MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01079819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, 0 mg, One daily, 1 Day
Study: NCT00513617
Drug: Arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
Study: NCT00513617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
Study: NCT00865007
Drug: Monotherapy (Lopinavir/ritonavir) + ABC/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI sparing regimen
Study: NCT00204022
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine
Study: NCT00213057
Drug: Carraguard (PC-515)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00462462
Drug: Ethanol 96% Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00462462
Drug: Ethanol 98% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02719795
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
Study: NCT00204789
Drug: Difluoromethylornithine
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02680275
Drug: Dead Sea Peloid Gel
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravaginally
Study: NCT00894517
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injected into the prostate on Day 1.
Study: NCT01470417
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
Study: NCT00002616
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04249778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a placebo to match 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
Study: NCT03223909
Drug: PRO-087
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
Study: NCT02066337
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03451006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo will be given in divided doses
Study: NCT03297294
Drug: EMA401
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, oral
Study: NCT03297294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to EMA401 capsules, oral
Study: NCT01221831
Drug: Estradiol valerate, dienogest and placebo tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-26: one tablet of Estradiol valerate/dienogest per day~* Days 26-28: one placebo tablet per day
Study: NCT02506231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02555982
Drug: BOTOX ® 200 Unités
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
Study: NCT02555982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
Study: NCT03988101
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
Study: NCT00062101
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02039063
Drug: E6011 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02039063
Drug: E6011 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02039063
Drug: E6011 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02039063
Drug: E6011 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00921284
Drug: NaCl 9/00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same volume as in the dexmedetomidine group
Study: NCT01935479
Drug: MN-10-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous administration of teriparatide acetate
Study: NCT01935479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo AK159
Study: NCT02740179
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone 50mg by mouth twice daily
Study: NCT02740179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth twice daily
Study: NCT02593487
Drug: Rosuvastatin 10mg/d group
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10mg tablet,q.d. for 12 weeks.
Study: NCT02593487
Drug: Rosuvastatin 20mg/d group
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20mg tablet,q.d. for 12 weeks.
Study: NCT01526460
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg
Study: NCT01526460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no statin loading dose
Study: NCT01039454
Drug: GSK598809 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
Study: NCT01039454
Drug: GSK598809 Placebo Capsules
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of substance dependence and potentially other impulse control disorders.
Study: NCT00265772
Drug: MODULEN IBD (R) (specific Enteral Nutrition)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00265772
Drug: prednisolon
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00749411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00749411
Drug: GSK233705/GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
Study: NCT00913003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
Study: NCT02377466
Drug: Placebo IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
Study: NCT02104817
Drug: Epanova® (omega-3 carboxylic acids)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
Study: NCT00000555
Drug: supplementation, food
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000555
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00114231
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02137382
Drug: Creon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: active comparator
Study: NCT01933919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matching to fluvoxamine maleate
Study: NCT03355352
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentail sublingual 15ug nanopills
Study: NCT02440035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.
Study: NCT00852917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Placebo tablet daily.
Study: NCT00005090
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/kg on day -2 (2 days before transplant).
Study: NCT00005090
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
Study: NCT02013427
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take one 500mg naproxen capsule twice a day.
Study: NCT02013427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one placebo capsule twice a day.
Study: NCT04403516
Drug: Prednisolone Acetate 1%
Normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.
Study: NCT02270424
Drug: Bufeijianpi granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
Study: NCT02270424
Drug: Bufeiyishen granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
Study: NCT03550534
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule was also obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
Study: NCT03326986
Drug: MK-7252
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
Study: NCT03326986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
Study: NCT02914769
Drug: Ayahuasca
Normalized name: ayahuasca
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive a single dose of ayahuasca.
Study: NCT02914769
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive a single dose of a passive placebo.
Study: NCT00607295
Drug: clino-san vaginal lubricant
Normalized name: Trimo San Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clino-san 2ml vaginal application 3 times per week for 12 weeks
Study: NCT03082235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatin capsules
Study: NCT01572519
Drug: Phase 1, Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.
Study: NCT01572519
Drug: Phase 1, Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.
Study: NCT01572519
Drug: Phase 1, Cohort 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
Study: NCT01572519
Drug: Phase 1, Cohort 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.
Study: NCT01572519
Drug: Phase 2
Normalized name: Premphase 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-40346527 at the recommended dose determined in Phase 1
Study: NCT00506506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00981799
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.
Study: NCT00981799
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Give between day 29 and 36 or when ANC\>750 and PLTS\>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but \<2 years of age 10 mg for patients age greater than or equal to 2, but \<3 years of age 12 mg for patients greater than or equal to 3, but \< 9 years of age 15 mg for patients greater than or equal to \>9 years of age
Study: NCT01201759
Drug: Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
Study: NCT04341454
Drug: DWP14012 X mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 X mg, tablet, orally, once daily for 2 weeks
Study: NCT04341454
Drug: DWP14012 X mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks
Study: NCT04341454
Drug: DWP14012 Y mg
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 Y mg, tablet, orally, twice daily for 2 weeks
Study: NCT04341454
Drug: DWP14012 Y mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks
Study: NCT04531787
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens
Study: NCT02480426
Drug: CO2 portograms guidance
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
Study: NCT02285634
Drug: Lidocaine 1% plus epinephrine 1:100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
Study: NCT02285634
Drug: Bacteriostatic 0.9% NaCL
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
Study: NCT00450983
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01514825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00957619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
Study: NCT00384293
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin (+) laropiprant (2 g) placebo po qd.
Study: NCT00194792
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00194792
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01226537
Drug: Taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg taurine capsules twice per day for 6 months
Study: NCT00430365
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo
Study: NCT03553563
Drug: D961H capsule 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: All Groups can select either capsule or sachet during the study.
Study: NCT02568709
Drug: Saline Nasal Spray
Normalized name: Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study: NCT00303277
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 40 mg tablets once per day for 12 weeks
Study: NCT00303277
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pravastatin 80 mg tablets once per day for 12 weeks
Study: NCT02766725
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal gel